Print
Email
Print Edition Stories
MHT's Julie Donnelly: Pharmaceuticals find drug development partners in colleges
Funding drugs for rare diseases
Cambridge small-molecule therapeutics developer Forma Therapeutics Inc. has signed a drug discovery collaboration agreement with Eisai Inc., the U.S. subsidiary of Tokyo pharmaceutical firm Eisai Co. Ltd.
As part of the deal, Forma will receive $20 million in upfront payments and funding from Eisai, as well as future milestone payments and royalties on products developed by Eisai that stem from the Forma collaboration.
The agreement calls for Eisai to have non-exclusive access to Forma’s Diversity Oriented Synthesis (DOS) chemistry, as well as its cell-based screening platforms.
Forma has used its DOS technology in another collaborative agreement with Emerald BioStructures, as it noted in its June partnership announcement.
Comments
If you are commenting using a Facebook account, your profile information may be displayed with your comment depending on your privacy settings. By leaving the 'Post to Facebook' box selected, your comment will be published to your Facebook profile in addition to the space below.
RSS Feeds
